Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
According to the MHRA/EMC SmPC for Wegovy, the most frequently reported gastrointestinal side effects include: Nausea the most common adverse effect, affecting approximately 44% of patients in clinical trials, typically most pronounced during dose escalation Diarrhoea reported in around 30% of patients, ranging from mild to moderate severity Constipation affecting approximately 24% of patients, related to slowed gut transit Vomiting occurring in roughly 24% of patients, often associated with nausea Abdominal pain or discomfort reported by approximately 20% of patients Dyspepsia (indigestion) affecting around 9% of patients Bloating and flatulence commonly reported but less precisely quantified in trials These side effects are dose-dependent , meaning they tend to be more pronounced at higher doses and during the escalation phase
"I was really struggling to get out on the bike, but when I went out on my bike for the first time, having lost that weight, it was just a game-changer
Less common but worth knowing about are nodules
Phase 2 dosing includes the following: However, the typical starting dose of retatrutide used in these trials is 1 mg or 2 mg once weekly, which is administered subcutaneously
Future research should focus on designing clinical trials that use fibrosis regression or synovitis reduction as primary endpoints in diseases like osteoarthritis, employing advanced imaging or histological techniques
However, there is an important caveat
